NCT03905252Completed
Biomarkers for Human Heart Failure
Source: ClinicalTrials.gov · Last updated 28 May 2024
Brief summary (registry, in English)
The purpose of this study is to establish the various ranges of proteins that can be assayed in the plasma and urine from hospitalized patients with all classes of heart failure and/or STEMI (ST-segment elevation myocardial infarction)/NSTEMI (Non-ST-segment elevation myocardial infarction), as well as history reviews.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 535 (actual)
- First submitted
- 4 Apr 2019
- Start date
- Aug 2009
- Primary completion date
- Feb 2024
- Lead sponsor
- Mayo Clinic
- Diseases
- Heart failure
- NCT number
- NCT03905252
What you commit to
- Study type: Observational
- Participants enrolled: 535
- From Aug 2009 to the primary completion date, Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Hemoglobin less than 10, active cancer, or amyloidosis Patient with dialysis
Who the study is looking for
- Diagnosis of Acute decompensated heart failure
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Foundation Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.